← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

SGHT logoSight Sciences, Inc.(SGHT)Earnings, Financials & Key Ratios

SGHT•NASDAQ
$4.30
$232M mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryVision, dental, and ENT devices
AboutSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.Show more
  • Revenue$77M-3.1%
  • EBITDA-$37M+26.5%
  • Net Income-$38M+25.4%
  • EPS (Diluted)-0.74+28.2%
  • Gross Margin86.17%+0.8%
  • EBITDA Margin-47.32%+24.1%
  • Operating Margin-47.95%+24.2%
  • Net Margin-49.67%+23.0%
  • ROE-50.74%-2.3%
  • ROIC-274.4%+9.4%
  • Debt/Equity0.64+38.3%
  • Interest Coverage-7.21+27.8%
Technical→

SGHT Key Insights

Sight Sciences, Inc. (SGHT) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 22.9%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

SGHT Price & Volume

Sight Sciences, Inc. (SGHT) stock price & volume — 10-year historical chart

Loading chart...

SGHT Growth Metrics

Sight Sciences, Inc. (SGHT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years22.86%
3 Years2.74%
TTM1.85%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM24.58%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM27.71%

Return on Capital

10 Years-85.68%
5 Years-33.64%
3 Years-33.55%
Last Year-32.03%

SGHT Recent Earnings

Sight Sciences, Inc. (SGHT) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Mar 4, 2026
EPS
$0.08
Est $0.15
+46.7%
Revenue
$20M
Est $20M
+0.2%
Q4 2025
Nov 6, 2025
EPS
$0.16
Est $0.26
+38.5%
Revenue
$20M
Est $20M
-2.2%
Q3 2025
Aug 7, 2025
EPS
$0.23
Est $0.25
+8.0%
Revenue
$20M
Est $18M
+10.3%
Q2 2025
May 8, 2025
EPS
$0.28
Est $0.29
+3.4%
Revenue
$18M
Est $18M
-5.3%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMar 4, 2026
$0.08vs $0.15+46.7%
$20Mvs $20M+0.2%
Q4 2025Nov 6, 2025
$0.16vs $0.26+38.5%
$20Mvs $20M-2.2%
Q3 2025Aug 7, 2025
$0.23vs $0.25+8.0%
$20Mvs $18M+10.3%
Q2 2025May 8, 2025
$0.28vs $0.29+3.4%
$18Mvs $18M-5.3%
Based on last 12 quarters of dataView full earnings history →

SGHT Peer Comparison

Sight Sciences, Inc. (SGHT) competitors in Vision, dental, and ENT devices — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
GKOS logoGKOSGlaukos CorporationDirect Competitor7.92B135.27-41.2432.33%-34.34%-26.46%0.21
ATRC logoATRCAtriCure, Inc.Direct Competitor1.42B28.01-116.7114.88%-0.83%-0.95%0.18
NVCR logoNVCRNovoCure LimitedDirect Competitor1.88B16.50-13.528.28%-25.66%-50.82%0.85
HOLX logoHOLXHologic, Inc.Product Competitor16.97B76.0130.531.74%13.18%10.37%0.52
MASI logoMASIMasimo CorporationProduct Competitor9.35B178.49-63.74-27.1%4.9%9.08%0.78
TNDM logoTNDMTandem Diabetes Care, Inc.Product Competitor1.24B18.03-5.937.93%-20.17%-141.98%2.86
ABT logoABTAbbott LaboratoriesSupply Chain149.97B86.2511.294.59%31.88%27.26%0.32
MDT logoMDTMedtronic plcSupply Chain99.48B77.6021.503.62%13%9.45%0.59

Compare SGHT vs Peers

Sight Sciences, Inc. (SGHT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs GKOS

Most directly comparable listed peer for SGHT.

Scale Benchmark

vs ABT

Larger-name benchmark to compare SGHT against a more recognizable public peer.

Peer Set

Compare Top 5

vs GKOS, ATRC, NVCR, HOLX

SGHT Income Statement

Sight Sciences, Inc. (SGHT) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue7.53M23.35M27.64M48.96M71.33M81.06M79.87M77.36M79.55M
Revenue Growth %-210.07%18.38%77.12%45.7%13.63%-1.47%-3.13%1.85%
Cost of Goods Sold2.34M6.54M9.21M8.61M12.36M11.88M11.58M10.7M11M
COGS % of Revenue31.05%28.03%33.32%17.59%17.33%14.66%14.5%13.83%-
Gross Profit
5.19M▲ 0%
16.8M▲ 223.7%
18.43M▲ 9.7%
40.35M▲ 118.9%
58.97M▲ 46.2%
69.17M▲ 17.3%
68.28M▼ 1.3%
66.67M▼ 2.4%
68.55M▲ 0%
Gross Margin %68.95%71.97%66.68%82.41%82.67%85.34%85.5%86.17%86.17%
Gross Profit Growth %-223.65%9.68%118.9%46.16%17.31%-1.29%-2.37%-
Operating Expenses19.49M40.84M50.62M91.82M142.92M126.45M118.82M103.77M104.2M
OpEx % of Revenue258.82%174.93%183.14%187.56%200.37%156%148.77%134.13%-
Selling, General & Admin14.06M32.72M41.74M76.19M120.06M108.89M100.83M89.16M91.48M
SG&A % of Revenue186.76%140.14%151.03%155.63%168.32%134.34%126.24%115.25%-
Research & Development5.43M8.12M8.87M15.63M22.86M17.56M17.99M14.61M12.72M
R&D % of Revenue72.06%34.8%32.11%31.93%32.05%21.66%22.53%18.88%-
Other Operating Expenses000000000
Operating Income
-14.3M▲ 0%
-24.04M▼ 68.1%
-32.19M▼ 33.9%
-51.48M▼ 59.9%
-83.95M▼ 63.1%
-57.27M▲ 31.8%
-50.53M▲ 11.8%
-37.1M▲ 26.6%
-35.65M▲ 0%
Operating Margin %-189.87%-102.96%-116.45%-105.15%-117.7%-70.66%-63.27%-47.95%-44.82%
Operating Income Growth %--68.14%-33.9%-59.93%-63.09%31.78%11.77%26.58%-
EBITDA-14.23M-23.61M-31.63M-50.28M-82.7M-56.66M-49.82M-36.61M-35.32M
EBITDA Margin %-189.03%-101.11%-114.45%-102.7%-115.94%-69.9%-62.38%-47.32%-44.39%
EBITDA Growth %--65.85%-34%-58.93%-64.49%31.49%12.07%26.51%28.05%
D&A (Non-Cash Add-back)63K432K554K1.2M1.25M614K712K487K338K
EBIT-14.3M-23.9M-32.23M-58.41M-81.73M-50.03M-46.61M-37.1M-24.25M
Net Interest Income1K-1.79M-2.37M-4.37M-4.47M-5.41M-4.66M-1.17M-2.02M
Interest Income1K174K30K00003.97M1.86M
Interest Expense01.96M2.4M4.37M4.47M5.41M4.66M5.14M2.61M
Other Income/Expense1K-1.82M-2.44M-11.29M-2.24M1.84M-739K-1.32M-1.62M
Pretax Income
-14.3M▲ 0%
-25.86M▼ 80.9%
-34.63M▼ 33.9%
-62.77M▼ 81.3%
-86.19M▼ 37.3%
-55.44M▲ 35.7%
-51.27M▲ 7.5%
-38.42M▲ 25.1%
-37.27M▲ 0%
Pretax Margin %-189.85%-110.76%-125.3%-128.22%-120.84%-68.39%-64.2%-49.66%-46.85%
Income Tax-6K8K61K188K47K110K236K10K-20K
Effective Tax Rate %0.04%-0.03%-0.18%-0.3%-0.05%-0.2%-0.46%-0.03%0.05%
Net Income
-14.29M▲ 0%
-25.87M▼ 81.0%
-34.69M▼ 34.1%
-62.96M▼ 81.5%
-86.24M▼ 37.0%
-55.55M▲ 35.6%
-51.51M▲ 7.3%
-38.43M▲ 25.4%
-37.25M▲ 0%
Net Margin %-189.77%-110.8%-125.52%-128.61%-120.9%-68.53%-64.49%-49.67%-46.83%
Net Income Growth %--81.03%-34.11%-81.48%-36.98%35.59%7.27%25.4%24.58%
Net Income (Continuing)-14.29M-25.87M-34.69M-62.96M-86.24M-55.55M-51.51M-38.43M-37.25M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)
-0.44▲ 0%
-0.77▼ 75.0%
-0.74▲ 3.9%
-1.33▼ 79.7%
-1.80▼ 35.3%
-1.14▲ 36.7%
-1.03▲ 9.6%
-0.74▲ 28.2%
-0.69▲ 0%
EPS Growth %--75%3.9%-79.73%-35.34%36.67%9.65%28.16%27.71%
EPS (Basic)-0.44-0.55-0.74-1.33-1.80-1.14-1.03-0.74-
Diluted Shares Outstanding32.2M33.63M46.77M47.5M47.85M48.63M50.13M52.15M53.94M
Basic Shares Outstanding32.2M33.63M46.77M47.5M47.85M48.63M50.13M52.15M53.94M
Dividend Payout Ratio---------

SGHT Balance Sheet

Sight Sciences, Inc. (SGHT) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets7.16M28M70.63M277.04M209.68M162.87M139.77M112.73M106.51M
Cash & Short-Term Investments4.24M21.24M61.51M260.69M185M138.13M120.36M91.97M84.96M
Cash Only4.24M21.24M61.51M260.69M185M138.13M120.36M91.97M84.96M
Short-Term Investments000000000
Accounts Receivable1.81M4.09M5.36M8.71M15.15M14.29M10.79M9.74M10.6M
Days Sales Outstanding87.986470.8264.9377.5164.3449.2945.9845.53
Inventory486K2.24M2.6M3.48M6.11M7.85M6.33M7.77M7.01M
Days Inventory Outstanding75.87125.16102.97147.31180.54241.13199.35265.02240.27
Other Current Assets00003.42M2.6M2.31M3.26M3.95M
Total Non-Current Assets930K2.74M2.17M3.15M3.4M3.78M3.06M2.57M3.19M
Property, Plant & Equipment868K2.57M1.79M2.95M3.19M3.1M2.52M2.05M2.82M
Fixed Asset Turnover8.68x9.08x15.47x16.60x22.40x26.16x31.76x37.77x34.83x
Goodwill000000000
Intangible Assets000000000
Long-Term Investments000000000
Other Non-Current Assets62K168K386K202K211K682K550K518K1.82M
Total Assets
8.09M▲ 0%
30.74M▲ 279.8%
72.81M▲ 136.8%
280.19M▲ 284.8%
213.07M▼ 24.0%
166.65M▼ 21.8%
142.84M▼ 14.3%
115.3M▼ 19.3%
109.7M▲ 0%
Asset Turnover0.93x0.76x0.38x0.17x0.33x0.49x0.56x0.67x0.69x
Asset Growth %-279.8%136.84%284.84%-23.95%-21.79%-14.29%-19.28%-72.26%
Total Current Liabilities2.9M7.34M9.31M13.5M17.82M12.25M15.47M11.03M18.16M
Accounts Payable1.88M2.31M2.16M3.35M2.69M1.73M1.69M1.34M1.49M
Days Payables Outstanding293.34129.1285.53142.0679.3753.1853.345.8355.12
Short-Term Debt000002.22M003.8M
Deferred Revenue (Current)000000000
Other Current Liabilities328K04.07M5.99M7.35M4.53M9.68M9.21M14.37M
Current Ratio2.47x3.82x7.58x20.52x11.77x13.29x9.04x10.22x10.22x
Quick Ratio2.31x3.51x7.30x20.26x11.43x12.65x8.63x9.52x9.52x
Cash Conversion Cycle-129.4960.0488.2670.19178.68252.3195.34265.18230.68
Total Non-Current Liabilities34.16M78.09M152.34M34.58M35.18M34.18M39.85M40.33M37.64M
Long-Term Debt34.15M12.86M31.95M32.66M33.31M31.71M39.36M40.3M0
Capital Lease Obligations0528K134K1.04M635K914K473K0230K
Deferred Tax Liabilities000000000
Other Non-Current Liabilities7K64.7M120.25M879K1.23M1.56M19K31K37.7M
Total Liabilities37.06M85.42M161.66M48.08M53M46.44M55.32M51.36M55.8M
Total Debt34.15M13.94M32.48M34.21M34.98M35.41M40.36M40.77M3.8M
Net Debt29.91M-7.3M-29.03M-226.48M-150.02M-102.72M-80M-51.19M-81.17M
Debt / Equity---0.15x0.22x0.29x0.46x0.64x0.64x
Debt / EBITDA---------0.11x
Net Debt / EBITDA--------2.30x
Interest Coverage--12.19x-13.41x-13.38x-18.30x-9.25x-10.00x-7.21x-9.29x
Total Equity
-28.96M▲ 0%
-54.68M▼ 88.8%
-88.85M▼ 62.5%
232.11M▲ 361.2%
160.08M▼ 31.0%
120.22M▼ 24.9%
87.52M▼ 27.2%
63.94M▼ 26.9%
53.9M▲ 0%
Equity Growth %--88.81%-62.48%361.24%-31.03%-24.9%-27.19%-26.94%-120.92%
Book Value per Share-0.90-1.63-1.904.893.352.471.751.231.00
Total Shareholders' Equity-28.96M-54.68M-88.85M232.11M160.08M120.22M87.52M63.94M53.9M
Common Stock9K9K9K48K48K49K51K54K54K
Retained Earnings-29.48M-55.35M-90.04M-153M-239.24M-294.79M-346.3M-384.72M-397.7M
Treasury Stock000000000
Accumulated OCI-34.15M-64.49M0000000
Minority Interest000000000

SGHT Cash Flow Statement

Sight Sciences, Inc. (SGHT) cash flow — operating, investing & free cash flow history

Line itemDec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations-14.47M-25M-32.17M-52.54M-75.97M-47.18M-22.35M-29.69M-29.69M
Operating CF Margin %-192.23%-107.06%-116.4%-107.32%-106.5%-58.21%-27.99%-38.38%-
Operating CF Growth %--72.69%-28.71%-63.3%-44.59%37.89%52.63%-32.85%-1444.27%
Net Income-14.29M-25.87M-34.69M-62.96M-86.24M-55.55M-51.51M-38.43M-37.25M
Depreciation & Amortization63K295K554K632K710K614K712K487K690K
Stock-Based Compensation52K118K497K5.08M12.96M14.58M17.08M13.05M11.66M
Deferred Taxes0007.76M00000
Other Non-Cash Items58K800K684K1.27M2.3M2.3M2.37M1.59M3.63M
Working Capital Changes-358K-341K784K-4.33M-5.7M-9.13M9M-6.39M-3.86M
Change in Receivables-1.42M-2.32M-1.48M-3.69M-6.84M661K3.54M912K-1.14M
Change in Inventory-184K-1.8M-1.72M-1.31M-3.25M-2.16M1.63M-1.44M-1.2M
Change in Payables1M168K448K1.17M-694K-883K336K-348K-943K
Cash from Investing-570K-672K-953K-813K-970K-791K-385K-224K-284K
Capital Expenditures-570K-672K-953K-813K-970K-791K-385K-224K-284K
CapEx % of Revenue7.57%2.88%3.45%1.66%1.36%0.98%0.48%0.29%-
Acquisitions000000000
Investments---------
Other Investing000000000
Cash from Financing12.2M42.66M73.4M252.53M1.25M1.1M4.96M1.79M1.86M
Debt Issued (Net)014M20.48M0004.15M00
Equity Issued (Net)12.23M30.75M53.08M256.68M1.25M1.33M1.07M1.85M1.76M
Dividends Paid000000000
Share Repurchases00000000-1K
Other Financing-23K-2.09M-154K-4.15M0-224K-261K-58K104K
Net Change in Cash
-2.84M▲ 0%
17M▲ 698.0%
40.27M▲ 137.0%
199.18M▲ 394.6%
-75.69M▼ 138.0%
-46.87M▲ 38.1%
-17.77M▲ 62.1%
-28.13M▼ 58.3%
-23.54M▲ 0%
Free Cash Flow
-15.04M▲ 0%
-25.67M▼ 70.6%
-33.13M▼ 29.1%
-53.35M▼ 61.1%
-76.94M▼ 44.2%
-47.98M▲ 37.6%
-22.74M▲ 52.6%
-29.92M▼ 31.6%
-25.4M▲ 0%
FCF Margin %-199.8%-109.94%-119.85%-108.98%-107.86%-59.19%-28.47%-38.67%-31.93%
FCF Growth %--70.61%-29.05%-61.06%-44.2%37.64%52.61%-31.59%-3.94%
FCF per Share-0.47-0.76-0.71-1.12-1.61-0.99-0.45-0.57-0.57
FCF Conversion (FCF/Net Income)1.01x0.97x0.93x0.83x0.88x0.85x0.43x0.77x0.68x
Interest Paid01.15M1.29M000001.06M
Taxes Paid000000000

SGHT Key Ratios

Sight Sciences, Inc. (SGHT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric2019202020212022202320242025TTM
Return on Equity (ROE)---87.9%-43.98%-39.64%-49.59%-50.74%-59.1%
Return on Invested Capital (ROIC)---686.25%-802.98%-311.76%-302.85%-274.4%-274.4%
Gross Margin71.97%66.68%82.41%82.67%85.34%85.5%86.17%86.17%
Net Margin-110.8%-125.52%-128.61%-120.9%-68.53%-64.49%-49.67%-46.83%
Debt / Equity--0.15x0.22x0.29x0.46x0.64x0.64x
Interest Coverage-12.19x-13.41x-13.38x-18.30x-9.25x-10.00x-7.21x-9.29x
FCF Conversion0.97x0.93x0.83x0.88x0.85x0.43x0.77x0.68x
Revenue Growth210.07%18.38%77.12%45.7%13.63%-1.47%-3.13%1.85%

SGHT SEC Filings & Documents

Sight Sciences, Inc. (SGHT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 6, 2026·SEC

Material company update

Apr 23, 2026·SEC

Material company update

Mar 30, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 4, 2026·SEC

FY 2025

Mar 7, 2025·SEC

FY 2024

Mar 13, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 6, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

SGHT Frequently Asked Questions

Sight Sciences, Inc. (SGHT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Sight Sciences, Inc. (SGHT) reported $79.6M in revenue for fiscal year 2025. This represents a 956% increase from $7.5M in 2018.

Sight Sciences, Inc. (SGHT) saw revenue decline by 3.1% over the past year.

Sight Sciences, Inc. (SGHT) reported a net loss of $37.3M for fiscal year 2025.

Dividend & Returns

Sight Sciences, Inc. (SGHT) has a return on equity (ROE) of -50.7%. Negative ROE indicates the company is unprofitable.

Sight Sciences, Inc. (SGHT) had negative free cash flow of $25.4M in fiscal year 2025, likely due to heavy capital investments.

Explore More SGHT

Sight Sciences, Inc. (SGHT) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.